MRK 全部观点

MRK 这一页 2 条观点条目,其中 0 条方向发生变化。

在本页筛选
David Lin 发布 2026-09-27
《‘Almost 0%’ Chance Stocks Are Higher In 10 Years | Bill Smead》
$MRK看涨
MRK是一项持仓,其保守的会计处理(研发费用化)表明其真实盈利能力更高。

我们持有 Merc 和 Amgen,我们喜欢这两家公司,因为它们的会计处理是所有大型公司中最保守的。我这话是什么意思?它们每年把收入的 18% 到 20% 投入研发,并在当期一次性计入费用。

计入费用。它们不做折旧摊销。这是它们所做的最重要的长期投资。所以,它们的利润表实际上比其他公司要赚钱得多,因为它们的会计处理如此保守。

we own Merc and Amgen, and we love those companies because they have the most conservative accounting of any major corporations. What do I mean by that? They spend 18 to 20% of of their revenue each year on R&D and expense it upfront.

Expense it. They don't depreciate. It's the most important long-term investment they make. So, their income statement, they are actually much more profitable as compared to other corporations because of how conservative their accounting is.

Schwab Network发布 2026-09-09
《The Big 3: ROST, MRK, AAPL》
$MRK看跌
Merck 当前的强势被视为一项负担;预计将出现下行,并通过约 100 天后到期的看跌价差为此布局。

另一只大幅上涨的是 Merc,这是你在这里三大标的中的第二个选择。他们公布了非常积极的试验消息,也许离治愈黑色素瘤,或者至少对它有一种深度治疗,又近了一步。但正在失去、维持不住动能。

它们上涨约 14%,但从那些高点回落。你怎么看 Merc?

Uh another one with a big runup is Merc, which is your second pick here in the big three. They came out with a really positive trial news. perhaps were one step closer uh to curing melanoma or having at least a profound treatment for it.

Uh but losing, you know, maintaining their momentum. They're up about 14% but falling off of those highs. How are you looking at Merc?

他说在等
跌破145.62处的21日EMA或三角形的下趋势线
价格收于这些技术位下方
近期数个交易日图表技术面
削弱看涨的相对强度叙事,并支持看跌论点
已经是最早的记录
其他股票的全部观点条目
把 $MRK 加入我的股票30 天完整试用
开始试用